Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-122 for Vasomotor Symptoms in Breast Cancer Patients
NCT04080297Phase 1Completed
- Sponsor
- QUE Oncology
- Start
- Jan 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of Q-122 in vasomotor symptoms (2 arms), sponsored by QUE Oncology. Primary endpoints: Adverse Event Reporting of Q-122 at 4 weeks, Serious Adverse Event Reporting of Q-122 at 4 weeks and 2 more. Started Jan 2014; status: completed.
02
Drugs
Q-122
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04080297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04080297.